Koyfin Home > Directory > Health Care > Antares Pharma > Long-Term Debt

Antares Pharma Long-Term Debt Chart (ATRS)

Antares Pharma annual/quarterly Long-Term Debt from 2000 to 2018.
  • Antares Pharma Long-Term Debt for the quarter ending December 12, 2018 was $25m a 0.80% increase of 0m year over year
  • Antares Pharma Long-Term Debt for the last 12 months ending December 12, 2018 was $25m a 0.80% increase of 0m year over year
  • Antares Pharma Annual Long-Term Debt for 2018 was $25m a 1.07% increase of 0m from 2017
  • Antares Pharma Annual Long-Term Debt for 2017 was $25m a 90.99% increase of 23m from 2016
  • Antares Pharma Annual Long-Term Debt for 2008 was $2m a -108.32% decrease of -2m from 2007
Other Cash Flow Metrics:
  • Antares Pharma Cash Flow from Operations for the quarter ending September 09, 2018 was $0m a -9,658.63% increase of 8m year over year
  • Antares Pharma Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $0m a -10,730.73% increase of 6m year over year
  • Antares Pharma Total Revenue for the quarter ending December 12, 2018 was $19m a 32.51% increase of 6m year over year
View Chart On Koyfin

Quarterly ATRS Long-Term Debt Data

12/2018$25m
09/2018$25m
06/2018$25m
03/2018$25m
12/2017$25m
09/2017$25m
06/2017$25m
06/2009$1m
03/2009$2m
12/2008$2m

Annual ATRS Long-Term Debt Data

2018$25m
2017$25m
2008$2m
2007$5m
2000$18m